Evans, Marc
Husain, Mansoor
Srivastava, Ayush
Mangla, Kamal Kant
Kuhlman, Anja Birk
Lingvay, Ildiko
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 6 October 2023
Accepted: 23 November 2023
First Online: 10 February 2024
Change Date: 13 March 2024
Change Type: Update
Change Details: The original article was revised due to addition of missing ESM file.
Declarations
:
: Marc Evans has received fees from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. Mansoor Husain has received research grants from AstraZeneca, Merck and Novo Nordisk; consultancy fees for participation in advisory board meetings from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Roche; speaker fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck and Novo Nordisk; and payment for expert testimony from Novo Nordisk. He holds one patent relating to GLP-1 peptides and has one patent pending relating to methods for inhibiting platelet aggregation using GLP-1 peptides. Ayush Srivastava is an employee of Novo Nordisk Service Centre Pvt. Ltd. Kamal Kant Mangla and Anja Birk Kuhlman are employees of Novo Nordisk A/S. Ayush Srivastava, Kamal Kant Mangla and Anja Birk Kuhlman hold Novo Nordisk stocks. Ildiko Lingvay has received research funding (paid to institution) from Boehringer Ingelheim, Merck, Mylan, Novo Nordisk, Pfizer and Sanofi; and advisory/consulting fees and/or other support from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia Therapeutics, Intercept Pharmaceuticals, Janssen, MannKind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Target Pharma, Valeritas and Zealand Pharma.
: The data analysed during the study were licensed under an agreement between Novo Nordisk and Merative. The study was performed in accordance with the Declaration of Helsinki (1964). Ethical approval and informed consent were not required, because these were fully anonymized data.